Friday, Sept. 25, 2015, 38 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,008.66 to $937,922,958.45.

Highlighted Stocks Traded by Insiders:

Smith & Wesson (SWHC) - FREE Research Report

Golden Michael F, who is Director at Smith & Wesson, sold 12,534 shares at $17.33 on Sept. 25, 2015. Following this transaction, the Director owned 287,073 shares meaning that the stake was reduced by 4.18% with the 12,534-share transaction.

The shares most recently traded at $17.14, down $0.19, or 1.09% since the insider transaction. Historical insider transactions for Smith & Wesson go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 12,021
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 12,021
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 83,769

The average volume for Smith & Wesson has been 869,600 shares per day over the past 30 days. Smith & Wesson has a market cap of $959.1 million and is part of the industrial goods sector and aerospace/defense industry. Shares are up 85.43% year-to-date as of the close of trading on Friday.

Smith & Wesson Holding Corporation manufactures and sells firearm products in the United States and internationally. The company operates in two segments, firearms and accessories. The company has a P/E ratio of 19.6. Currently, there are 6 analysts who rate Smith & Wesson a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWHC - FREE

TheStreet Quant Ratings rates Smith & Wesson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Smith & Wesson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hess (HES) - FREE Research Report

Wilson Robert N, who is Director at Hess, bought 3,000 shares at $49.76 on Sept. 25, 2015. Following this transaction, the Director owned 78,230 shares meaning that the stake was boosted by 3.99% with the 3,000-share transaction.

The shares most recently traded at $49.20, down $0.56, or 1.14% since the insider transaction. Historical insider transactions for Hess go as follows:

  • 4-Week # shares bought: 119,890
  • 4-Week # shares sold: 4,300
  • 12-Week # shares bought: 119,890
  • 12-Week # shares sold: 4,300
  • 24-Week # shares bought: 119,890
  • 24-Week # shares sold: 11,800

The average volume for Hess has been 3.2 million shares per day over the past 30 days. Hess has a market cap of $14.4 billion and is part of the basic materials sector and energy industry. Shares are down 31.9% year-to-date as of the close of trading on Friday.

Hess Corporation, an exploration and production company, develops, produces, purchases, transports, and sells crude oil, natural gas liquids, and natural gas. The stock currently has a dividend yield of 2%. Currently, there are 9 analysts who rate Hess a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HES - FREE

TheStreet Quant Ratings rates Hess as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Hess Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Iridex (IRIX) - FREE Research Report

Paragon Associates & Paragon Associates Ii Joint Venture, who is 10% Owner at Iridex, bought 52,042 shares at $7.05 on Sept. 25, 2015. Following this transaction, the 10% Owner owned 1.3 million shares meaning that the stake was boosted by 4.34% with the 52,042-share transaction.

The shares most recently traded at $6.70, down $0.35, or 5.21% since the insider transaction. Historical insider transactions for Iridex go as follows:

  • 4-Week # shares bought: 22,170
  • 4-Week # shares sold: 561
  • 12-Week # shares bought: 174,758
  • 12-Week # shares sold: 2,616
  • 24-Week # shares bought: 174,758
  • 24-Week # shares sold: 4,063

The average volume for Iridex has been 31,500 shares per day over the past 30 days. Iridex has a market cap of $69.8 million and is part of the health care sector and health services industry. Shares are down 18.72% year-to-date as of the close of trading on Friday.

IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases. The company has a P/E ratio of 8.1. Currently, there are no analysts who rate Iridex a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRIX - FREE

TheStreet Quant Ratings rates Iridex as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Iridex Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.